Kitano Yasunori, Suzuki Tsuyoshi, Kawahara Eiji, Yamazaki Takahisa
Mitsubishi Pharma Corporation, Pharmaceuticals Research Division, 1000, Kamoshida-cho, Aoba-ku, Yokohama 227-0033, Japan.
Bioorg Med Chem Lett. 2007 Nov 1;17(21):5863-7. doi: 10.1016/j.bmcl.2007.08.020. Epub 2007 Aug 15.
The present study identified several 4-alkynyl and 4-alkenylquinazolines that serve as novel and potent EGFR tyrosine kinase inhibitors. The IC(50) values of these compounds are in the nanomolar range. In addition, the 4-(4-phenylbut-1-yn/en-yl)quinazolines provided scaffolds for potent enzyme inhibition. Chiral discrimination was observed to occur in one of the 4-alkynylquinazoline derivatives with the (R)-isomer being more than 150 times as potent as the (S)-isomer.
本研究鉴定出了几种4-炔基和4-烯基喹唑啉,它们是新型强效表皮生长因子受体(EGFR)酪氨酸激酶抑制剂。这些化合物的半数抑制浓度(IC50)值处于纳摩尔范围。此外,4-(4-苯基丁-1-炔/烯)喹唑啉为强效酶抑制提供了骨架。在一种4-炔基喹唑啉衍生物中观察到了手性识别现象,其中(R)-异构体的效力是(S)-异构体的150倍以上。